title: Treatment Options for Medulloblastoma and CNS Primitive Neuroectodermal Tumor (PNET).
abstract: Medulloblastoma and central nervous system (CNS) primitive neuroectodermal tumor (PNET) are primary pediatric brain tumors that require multidisciplinary therapies. Although often treated similarly in clinical trials, they are biologically different diseases. Even within medulloblastomas and CNS PNETs, there are molecularly distinct subgroups with differing presentations and prognoses. Overall, prognosis is better for medulloblastomas. Specific treatments for these types of cancer are continuously evolving to maximize survival and minimize long-term sequelae of treatment. Patients should be treated on a clinical trial, if eligible, as they may gain benefit with minimal risk over current standard of care. The amount of residual disease after surgery better correlates with survival for medulloblastomas than for CNS PNETs. Maximal surgical resection of tumor should be done, only if additional permanent, neurologic deficits can be spared. Patients should have a staging work-up to assess the extent of disease. This includes postoperative magnetic resonance imaging (MRI) of the brain, MRI of the entire spine and lumbar cerebrospinal fluid (CSF) sampling for cytological examination, if deemed safe. Radiation therapy to the entire CNS axis is required, with a greater dose (boost) given to the region of the primary site or any bulky residual disease for older children. Adjuvant chemotherapy must be given even if no evidence of disease after radiation therapy exists, as the risk of relapse is substantial after radiation alone. Subsets of younger children with medulloblastoma, arbitrarily defined as those younger than 3 years of age in some studies and 4 or even 5 years in other studies, can be effectively treated with chemotherapy alone. Recent genomic studies have revealed further subtypes of disease than previously recognized. Clinical trials to exploit these biologic differences are required to assess potential efficacy of targeted agents. The treatment of medulloblastoma and CNS PNET can cause significant impairment in neurologic function. Evaluations by physical therapy, occupational therapy, speech therapy and neurocognitive assessments should be obtained, as needed. After therapy is completed, survivors need follow-up of endocrine function, surveillance scans and psychosocial support.
authors: Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY, 10065, USA, debragak@mskcc.org.
authors: Kevin C
authors: KC
authors: De Braganca
authors: Roger J
authors: RJ
authors: Packer
references: Am J Phys Med Rehabil. 2011 May;90(5 Suppl 1):S50-62
references: 21765264
references: J Natl Cancer Inst. 2008 Jun 4;100(11):773-83
references: 18505970
references: J Clin Oncol. 1999 Mar;17(3):832-45
references: 10071274
references: Med Pediatr Oncol. 1990;18(4):304-10
references: 2355890
references: Cancer. 2007 Nov 1;110(9):2035-41
references: 17823910
references: Lancet Oncol. 2005 Aug;6(8):573-80
references: 16054568
references: Lancet Oncol. 2012 Aug;13(8):838-48
references: 22691720
references: J Neurooncol. 2012 May;108(1):153-61
references: 22350432
references: Cancer J. 2004 Nov-Dec;10(6):386-90
references: 15701271
references: Pediatr Blood Cancer. 2007 Mar;48(3):278-84
references: 16456857
references: Curr Oncol. 2009 Dec;16(6):21-8
references: 20016743
references: J Clin Oncol. 2009 Jun 1;27(16):2677-85
references: 19364965
references: J Clin Oncol. 2005 Oct 20;23(30):7621-31
references: 16234523
references: J Clin Oncol. 2005 Aug 20;23(24):5511-9
references: 16110011
references: Handb Clin Neurol. 2012;105:529-48
references: 22230517
references: Med Pediatr Oncol. 1987;15(5):241-53
references: 3309606
references: Neurosurgery. 2000 Sep;47(3):623-31; discussion 631-2
references: 10981749
references: Ann Neurol. 1992 Oct;32(4):551-4
references: 1456739
references: Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):1145-52
references: 7607936
references: Cancer. 2005 May 1;103(9):1874-80
references: 15770645
references: J Clin Oncol. 2004 Dec 15;22(24):4881-7
references: 15611503
references: Cancer Treat Rev. 2003 Oct;29(5):417-30
references: 12972360
references: Pediatr Neurosci. 1985-1986;12(4-5):272-82
references: 3039477
references: Acta Neuropathol. 2007 Aug;114(2):97-109
references: 17618441
references: Neuro Oncol. 2009 Apr;11(2):201-10
references: 18818397
references: N Engl J Med. 2006 Oct 12;355(15):1572-82
references: 17035650
references: J Clin Oncol. 2003 Sep 1;21(17):3255-61
references: 12947060
references: Med Pediatr Oncol. 2002 Sep;39(3):190-4
references: 12210449
references: Pediatr Blood Cancer. 2008 Jun;50(6):1169-75
references: 18293379
references: Nature. 2002 Jan 24;415(6870):436-42
references: 11807556
references: J Neurooncol. 2004 Feb;66(3):345-50
references: 15015667
references: Acta Neuropathol. 2012 Apr;123(4):473-84
references: 22358457
references: Cancer. 2003 Sep 1;98(5):1014-20
references: 12942570
references: Cancer. 1994 Oct 15;74(8):2352-60
references: 7922986
references: J Neurosurg. 1990 Apr;72(4):572-82
references: 2319316
references: Acta Neuropathol. 2012 Apr;123(4):465-72
references: 22134537
references: N Engl J Med. 2005 Mar 10;352(10):978-86
references: 15758008
references: Neurosurgery. 1996 Feb;38(2):265-71
references: 8869053
references: J Neurooncol. 2012 May;107(3):537-44
references: 22124725
references: J Neurosurg Pediatr. 2010 Apr;5(4):329-34
references: 20367335
references: J Pediatr Hematol Oncol. 2008 Nov;30(11):791-7
references: 18989154
references: Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):e15-20
references: 21481547
references: Arch Neurol. 2008 Nov;65(11):1419-24
references: 19001159
references: Semin Oncol. 2004 Oct;31(5):666-75
references: 15497120
references: Int J Radiat Oncol Biol Phys. 1984 Oct;10(10):1851-3
references: 6593316
references: Cancer. 2011 Jul 15;117(14):3262-7
references: 21246528
references: Neuro Oncol. 2013 Jan;15(1):97-103
references: 23099653
references: Acta Paediatr Scand. 1975 May;64(3):399-403
references: 1057366
references: Neurology. 2007 Mar 20;68(12):932-8
references: 17372129
references: Pediatr Neurosurg. 2003 Jul;39(2):60-7
references: 12845195
references: J Clin Oncol. 2006 Sep 1;24(25):4202-8
references: 16943538
references: J Neuropathol Exp Neurol. 2004 May;63(5):441-9
references: 15198123
references: J Neurosurg. 2006 Dec;105(6 Suppl):444-51
references: 17184075
references: Pediatr Blood Cancer. 2009 Aug;53(2):261-6
references: 19326418
references: J Clin Oncol. 2005 Oct 1;23(28):7152-60
references: 16192599